Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Inventory: 2012-2024

Historic Inventory for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $136.8 million.

  • Ani Pharmaceuticals' Inventory fell 1.06% to $146.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.5 million, marking a year-over-year decrease of 1.06%. This contributed to the annual value of $136.8 million for FY2024, which is 23.01% up from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Inventory is $136.8 million, which was up 23.01% from $111.2 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Inventory ranged from a high of $136.8 million in FY2024 and a low of $66.0 million during FY2020.
  • For the 3-year period, Ani Pharmaceuticals' Inventory averaged around $117.8 million, with its median value being $111.2 million (2023).
  • Data for Ani Pharmaceuticals' Inventory shows a peak YoY spiked of 35.45% (in 2021) over the last 5 years.
  • Ani Pharmaceuticals' Inventory (Yearly) stood at $66.0 million in 2020, then spiked by 35.45% to $89.4 million in 2021, then increased by 17.79% to $105.4 million in 2022, then grew by 5.54% to $111.2 million in 2023, then climbed by 23.01% to $136.8 million in 2024.